Janus Henderson Investors US’s AstraZeneca AZN Stock Holding History

Janus Henderson Investors US’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	$21.7M	Buy	348,127 +69,279	+25%	+$4.03M	0.02%	598
2016 Q4	$15.2M	Sell	278,848 -26,116	-9%	-$1.48M	0.01%	664
2016 Q3	$20M	Sell	304,964 -4,818	-2%	-$315K	0.02%	589
2016 Q2	$18.7M	Buy	309,782 +62,768	+25%	+$3.65M	0.02%	586
2016 Q1	$13.9M	Buy	247,014 +32,452	+15%	+$1.95M	0.01%	623
2015 Q4	$14.6M	Buy	214,562 +32,954	+18%	+$2.16M	0.01%	653
2015 Q3	$11.6M	Buy	+181,608	New	+$11.9M	0.01%	694
2015 Q1	–	Sell	-744,205	Closed	-$52.4M	–	1106
2014 Q4	$52.4M	Buy	744,205 +31,428	+4%	+$2.25M	0.04%	435
2014 Q3	$50.9M	Sell	712,777 -383,117	-35%	-$28M	0.05%	412
2014 Q2	$81.4M	Sell	1,095,894 -261,018	-19%	-$18.9M	0.07%	319
2014 Q1	$88M	Buy	1,356,912 +122,341	+10%	+$7.9M	0.08%	294
2013 Q4	$73.3M	Buy	+1,234,571	New	+$67.1M	0.07%	321

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

EIP

Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Janus Henderson Investors US's AZN Position: Q1 2017 in Review

Janus Henderson Investors US increased its AstraZeneca (AZN) stake by 25% in Q1 2017, buying an estimated $4.03M and bringing the position to 348,127 shares worth $21.7M. The position accounts for 0.02% of the portfolio, ranked #598.

Janus Henderson Investors US first reported a position in AZN in Q4 2013 and has held it in 12 quarters since. The position peaked at $88M in Q1 2014. 461 funds tracked by Wall St. Rank hold AZN as of Q1 2017.

Janus Henderson Investors US held 348,127 shares of AstraZeneca worth $21.7M as of Q1 2017.
Janus Henderson Investors US bought 69,279 AstraZeneca shares in Q1 2017, an estimated $4.03M.
AstraZeneca made up 0.02% of Janus Henderson Investors US's portfolio in Q1 2017, its #598 holding.
Janus Henderson Investors US first reported a position in AstraZeneca in Q4 2013 and has held it in 12 quarters since.
Janus Henderson Investors US's AstraZeneca position peaked at $88M in Q1 2014.
461 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2017.

Based on Janus Henderson Investors US's 13F filing for Q1 2017, filed 16 May 2017.